Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

Abbreviated Name
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection
Lead Investigator
Liu, Alvin Y. — University of Washington
Coordinating Investigator
Liu, Alvin Y. — University of Washington
Involved Investigators

Abstact

Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.

Aims

To develop multiple reaction monitoring (MRM) proteomics to measure CD90 in urine samples of pre-op(erative) prostate cancer, biopsy negative, post-op, pre-op bladder cancer, and non-cancer. MRM uses triple quadrupole mass spectrometer and synthetic isotopically labeled CD90 signature peptides for detection at the fmol level.

Analytic Method

Genomic (Affymetrix GeneChip) analysis of sorted cancer cells and their normal counterpart (CD26+ prostate cancer vs. CD26+ luminal; CD90+ tumor-associated stromal vs. CD49a+ stromal; CD9+ bladder cancer vs. CD9+ superficial urothelial) to identify up-regulated genes encoding secreted or extracellular proteins. Proteomic analysis based on mass spectrometry to measure urinary levels of the protein candidates identified.

Comments

Since CD90 is expressed by many other cell types (e.g., T cells), its prostate cancer specificity as a urinary marker needs to be rigorously tested.

Outcome

Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.

Publications

Biomarkers

Data Collections

Start Date
Jan 1 2008
Estimated Finish Date
Dec 31 2008
Protocol ID
201
Protocol Type
Collaboration
Field of Research
Genomics
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate
Phased Status
2

Associated Forms